Share ownership argenx SE

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 21/01/2026 GMT			After hours 19:24:20
696.00 ^EUR	+1.49%		695.30	-0.10%

01-13	European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading	MT
01-13	Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	MT

Share class: argenx SE

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	60,760,957	60,295,150 ( 99.23 %)	0	99.23 %

Major shareholders: argenx SE

Name	Equities	%	Valuation
Wellington Management Co. LLP 2.955 %	1,819,494	2.955 %	1 532 M €
Norges Bank Investment Management 2.827 %	1,740,588	2.827 %	1 465 M €
Capital Research & Management Co. (World Investors) 0.3337 %	205,430	0.3337 %	173 M €
Sjunde AP-fonden 0.1314 %	80,902	0.1314 %	68 M €
State Street Global Advisors Ltd. 0.1229 %	75,647	0.1229 %	64 M €
HBM Partners AG (Investment Management) 0.0853 %	52,500	0.0853 %	44 M €
Lazard Asset Management Ltd. 0.0693 %	42,643	0.0693 %	36 M €
Fineco Asset Management DAC 0.0628 %	38,672	0.0628 %	33 M €
Storebrand Asset Management AS 0.0514 %	31,662	0.0514 %	27 M €
State Street Global Advisors Europe Ltd. 0.0468 %	28,843	0.0468 %	24 M €
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 9.245 %	5,692,346	9.245 %	4 787 M €
T. Rowe Price International Ltd. 5.913 %	3,640,409	5.913 %	3 061 M €
Janus Henderson Investors US LLC 4.183 %	2,575,251	4.183 %	2 166 M €
Artisan Partners Holdings LP 3.551 %	2,186,510	3.551 %	1 839 M €
Capital Research & Management Co. (World Investors) 3.183 %	1,959,504	3.183 %	1 648 M €
Avoro Capital Advisor LLC 1.608 %	990,000	1.608 %	833 M €
ClearBridge Investments LLC 1.229 %	756,862	1.229 %	636 M €
Wellington Trust Co., NA 1.186 %	729,986	1.186 %	614 M €
Citadel Securities GP LLC 1.159 %	713,559	1.159 %	600 M €
RTW Investments LP 1.094 %	673,497	1.094 %	566 M €
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	49.89%
Other	6.74%
SEI Investments Co.	0.51%
Manulife Financial Corp.	0.11%
Individuals	0.05%
State Street Corp.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Unknown	42.68%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	42.98%
United Kingdom	7.31%
Norway	2.93%
Switzerland	1.13%
Canada	0.75%
France	0.51%
Ireland	0.37%
Germany	0.26%
Sweden	0.23%
Luxembourg	0.23%
Netherlands	0.15%
Australia	0.09%
Italy	0.07%
Individuals	0.05%
Austria	0.04%
Japan	0.04%
Belgium	0.03%
Finland	0.03%
Denmark	0.02%
Singapore	0.02%
Spain	0.02%
China	0.01%
Taiwan	0.01%
Hong Kong	0.01%
South Africa	0.01%
Slovenia	0.01%

Based on 1000 largest holdings

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.

Employees

1,599

Sector

Biotechnology & Medical Research

Calendar

02-26 - Q4 2025 Earnings Release

More about the company